Sebastian Szpakowski
Sebastian Szpakowski
NIBR
Verified email at novartis.com
Title
Cited by
Cited by
Year
Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated …
DE Fouts, R Pieper, S Szpakowski, H Pohl, S Knoblach, MJ Suh, ...
Journal of translational medicine 10 (1), 1-17, 2012
2882012
Next generation sequencing to define prokaryotic and fungal diversity in the bovine rumen
DE Fouts, S Szpakowski, J Purushe, M Torralba, RC Waterman, ...
PloS one 7 (11), e48289, 2012
2232012
Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements
S Szpakowski, X Sun, JM Lage, A Dyer, J Rubinstein, D Kowalski, ...
Gene 448 (2), 151-167, 2009
1172009
MicroRNA signatures differentiate melanoma subtypes
E Chan, R Patel, S Nallur, E Ratner, A Bacchiocchi, K Hoyt, S Szpakowski, ...
Cell cycle 10 (11), 1845-1852, 2011
1042011
Phosphoproteomic screen identifies potential therapeutic targets in melanoma
K Tworkoski, G Singhal, S Szpakowski, CI Zito, A Bacchiocchi, ...
Molecular cancer research 9 (6), 801-812, 2011
912011
Phase 2 Study of the HSP-90 Inhibitor AUY922 in previously treated and molecularly defined patients with advanced non–small cell lung cancer
E Felip, F Barlesi, B Besse, Q Chu, L Gandhi, SW Kim, E Carcereny, ...
Journal of Thoracic Oncology 13 (4), 576-584, 2018
422018
Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
362019
PD-1 blockade in anaplastic thyroid carcinoma
J Capdevila, LJ Wirth, T Ernst, S Ponce Aix, CC Lin, R Ramlau, MO Butler, ...
Journal of Clinical Oncology 38 (23), 2620-2627, 2020
322020
Microbiome in human health and disease
R Madupu, S Szpakowski, KE Nelson
Science progress 96 (2), 153-170, 2013
262013
Using Bayesian modelling to investigate factors governing antibiotic-induced Candida albicans colonization of the GI tract
J Shankar, NV Solis, S Mounaud, S Szpakowski, H Liu, L Losada, ...
Scientific reports 5 (1), 1-11, 2015
252015
Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells
X Huang, R Narayanaswamy, K Fenn, S Szpakowski, C Sasaki, J Costa, ...
DNA and cell biology 31 (S1), S-2-S-10, 2012
182012
A systematic evaluation of high-dimensional, ensemble-based regression for exploring large model spaces in microbiome analyses
J Shankar, S Szpakowski, NV Solis, S Mounaud, H Liu, L Losada, ...
BMC bioinformatics 16 (1), 1-18, 2015
162015
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
DSW Tan, DW Kim, M Thomas, S Pantano, Y Wang, SL Szpakowski, ...
Journal of Clinical Oncology 34 (15_suppl), 9064-9064, 2016
152016
MU2A—reconciling the genome and transcriptome to determine the effects of base substitutions
V Garla, Y Kong, S Szpakowski, M Krauthammer
Bioinformatics 27 (3), 416-418, 2011
92011
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
SA Piha-Paul, MH Taylor, D Spitz, L Schwartzberg, JT Beck, TM Bauer, ...
Oncotarget 10 (60), 6526, 2019
82019
Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC)
DWT Lim, HM Wang, SH Li, R Ngan, A Dechaphunkul, L Zhang, CJ Yen, ...
Cancer Research 79 (13 Supplement), CT150-CT150, 2019
82019
Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071
S Piperno-Neumann, J Larkin, RD Carvajal, JJ Luke, GK Schwartz, ...
Molecular cancer therapeutics 19 (4), 1031-1039, 2020
62020
Methylation biomarkers and methods of use
PM Lizardi, S Szpakowski, M Chen, J Costa, H Zhao
US Patent App. 13/390,669, 2012
62012
Abstract CT034: Phase I study of WNT974+ spartalizumab in patients (pts) with advanced solid tumors
F Janku, F de Vos, M de Miguel, P Forde, A Ribas, M Nagasaka, G Argiles, ...
Cancer Research 80 (16 Supplement), CT034-CT034, 2020
52020
YAP: A Computationally Efficient Workflow for Taxonomic Analyses of Bacterial 16S and Fungal ITS Sequences. GitHub. 2013
S Szpakowski, A Tovchigrechko
52015
The system can't perform the operation now. Try again later.
Articles 1–20